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Abstract
Introduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing/remitting course with
transmural inflammation of potentially any section of the digestive tract. Certolizumab pegol (CZP) is a pegylated Fc-free Fab’ fragment
of a humanized anti-TNF-alfa monoclonal antibody that is in development for clinical use in CD.
Aims: To review the available data with CZP in CD, to investigate its possible place in therapy.
Evidence review: Available studies suggest that CZP has the potential to achieve and maintain clinical response and remission in
moderate to severe CD, and to improve quality of life compared with placebo. Further studies with CZP are also ongoing.
Place in therapy: Although only suggested by currently available studies, successive clinical practice and further ongoing trials may
confirm a positive role for CZP as a new anti-TNF treatment in CD. The impact on clinical management or on resources cannot be
estimated until the results from all phase III clinical trials are available and the price is determined.
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Core evidence place in therapy summary for certolizumab pegol in Crohn’s disease
Outcome measure Evidence Implications
Patient-oriented evidence
Easier subcutaneous use Substantial Possible better patient compliance and minor costs compared with intravenous
anti-TNF agents
Improvement in intestinal symptoms (clinical
response) in active disease
Moderate More data on induction requested by FDA. No direct comparison with steroids
or infliximab or adalimumab
Total regression of symptoms (clinical remission) Moderate More data on induction requested by FDA. No direct comparison with steroids
or infliximab or adalimumab
Maintenance of long-term response Substantial Further studies ongoing
Improvement in quality of life Substantial Beneficial effects on patient-perceived quality of life
Steroid-sparing effect Not available Study ongoing
Disease-oriented evidence
Mucosal healing Not available Study ongoing
Lower incidence of side effects Substantial Long-term data required
Lower incidence of antidrug antibodies and
autoantibodies
Substantial No definite evidence for better immunogenicity profile
Efficacy on extraintestinal manifestations Not available Further studies required
Efficacy in fistulizing disease Not available Further studies required
Improvement of natural history of the disease Not available Further studies required
Economic evidence
Cost effectiveness Not available Evidence required, even if theoretically positive
FDA, Food and Drug Administration; TNF, tumor necrosis factor.
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Scope, aims, and objectives
Certolizumab pegol (CZP, Cimzia™), previously named
CDP870, is being developed by UCB for clinical use in Crohn’s
disease (CD). It is a polyethylene glycol (PEG)-conjugated,
humanized, antigen-binding fragment (Fab’) of an anti-tumor
necrosis factor alfa (TNF-alfa) monoclonal antibody (mAb) to be
administered subcutaneously.
An extensive phase III trial program to explore CZP in moderate
to severe CD has been developed. The purpose of this article is
to review the available data on CZP to investigate its possible role
in clinical management of CD, which is important at this stage in
its development to highlight some critical issues for its optimal
use. Results obtained with other agents are briefly reviewed for
comparative purposes.
Methods
Electronic searches were conducted using PubMed, Scopus, and
clinical trial registries (http://www.clinicaltrials.gov) databases
from the earliest records to September 2007. The search terms
used were “certolizumab pegol,” “CDP870,” “therapy,”
“biologicals,” “inflammatory bowel disease,” and “Crohn’s
disease”. Reference lists of all relevant articles were searched for
further studies. Of the identified studies only articles published in
the English language were selected. Abstracts and other material
from meetings were also included in the analysis.
The levels of evidence identified from the literature searches are
summarized in Table 1. Twenty-six full papers and no abstracts
were identified in the initial search. Records were manually
reviewed and eight full-text papers were excluded because of
their redundancy as low-quality review of data available
elsewhere. After an additional search, a total of 21 full papers and
22 abstracts were identified. Among these, five full papers and
11 abstracts were considered for final analysis concerning clinical
efficacy and safety of CZP in CD.
Disease overview
Crohn’s disease is a chronic inflammatory bowel disease (IBD)
characterized by a relapsing/remitting course with transmural
inflammation of potentially any section of the digestive tract,
leading to various intestinal (internal and external fistulas,
intestinal strictures, abdominal and perianal abscesses) and
extraintestinal manifestations (Podolski 2002). Its incidence is five
out of 100 000 people and its prevalence is estimated to be 30–50
out of 100 000 people in Western countries. The disease
represents an important public health problem as it tends to affect
young people and have a chronic course affecting quality of life,
social activities, and working abilities (Shanahan 2002).
While the etiology remains unknown, the understanding of the
molecular mediators and mechanisms of tissue injury have greatly
advanced (Ardizzone & Bianchi Porro 2005). The disease has
been suggested to develop in a genetically predisposed subject
due to a disregulated immune response to unknown antigens
(probably environmental or infective, including endogenous
microflora), resulting in continuous immune-mediated
inflammation (Ardizzone & Bianchi Porro 2002a).
In the absence of a well-defined etiology, current treatment
protocols are aimed at modulating, by various approaches, the
complex inflammatory events leading to intestinal injury (Travis et
al. 2006). However, the treatments currently available cannot be
considered curative and, even today, up to 70% of patients
undergo surgery due to complications of the disease. Moreover,
an important subgroup of patients fail to show a significant
benefit from conventional treatments, thus delineating the
particular scenario of refractory CD and the need for novel
therapeutic strategies.
The proinflammatory cytokine TNF-alfa is a key mediator of
inflammation associated with CD (Breese & McDonald 1995). Its
biological activities include the induction of proinflammatory
cytokines such as interleukin (IL)-1 and IL-6, activation of
neutrophils, and enhancement of leucocyte migration (Papadakis
& Targan 2000). Increased levels of TNF-alfa are found in diseased
areas of the bowel wall, and in the blood and stools of patients
with CD, compared with normal controls (Braegger et al. 1992;
Murch et al. 1993; Reinecker et al. 1993).
Current therapy options
Current therapeutic management of CD is usually defined
as a “step-up” strategy, based on the use of drugs with
a gradually increasing strength of action, according to
disease extension, severity (mild, moderate, or severe),
activity (induction vs maintenance therapy), disease
pattern (inflammatory, penetrating-fistulizing, or stricturing),
response to current or prior medications, and the presence of
complications (Ardizzone & Bianchi Porro 2005). Available
treatments aim to induce remission, prevent relapses, improve
quality of life, and address complications. Conventional drugs
used in CD consist of aminosalicylates, corticosteroids,
immunosuppressors (azathioprine, 6-mercaptopurine,
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Category Number of records
Full papers Abstracts
Initial search 26 0
records excluded 8 0
records included 18 0
Additional studies identified 3 22
Level 1 clinical evidence
(systematic review, meta analysis)
1 0
Level 2 clinical evidence (RCT) 4 11
Level ≥3 clinical evidence 0 0
Economic evidence 0 0
Total records included 5 11
For definition of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review
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methotrexate) and immunomodulators such as infliximab and,
more recently, adalimumab.
Aminosalicylates are considered first-line therapy for mild to
moderate CD, although their efficacy is controversial and data
from recent reviews and meta analyses suggest their substantial
inefficacy in CD (Cammà et al. 1997).
Corticosteroids are indicated for moderate to severe active CD or
for patients who do not respond to first-line therapy. They induce
remission in 48% of patients and improve symptoms in another
32% within 30 days of treatment start, whereas 20% of patients
are resistant from onset (Munkholm et al. 1994). Although
corticosteroids can suppress active inflammation in the acute
setting, they are ineffective maintenance agents, and long-term
use is associated with important side effects (such as
osteoporosis, hypertension, diabetes mellitus, and ocular
complications) and high relapse rates, often complicated by the
occurrence of steroid dependency or refractoriness. Indeed,
1 year after starting corticosteroids, only 32% of CD patients are
corticosteroid-free without surgery, which underscores the
importance of maintenance therapy after a corticosteroid-induced
remission (Faubion et al. 2001).
The thiopurines azathioprine and 6-mercaptopurine are effective
maintenance agents, including in steroid-dependent patients
(Caprilli et al. 2005a), with 42% of patients treated with
azathioprine achieving remission at 15 months after induction
with glucocorticoids compared with only 7% in the placebo group
(Candy et al. 1995). However, these drugs act slowly (Present et
al. 1980) and they are limited by potentially important adverse
events, with 10–20% of patients being intolerant of them.
Methotrexate can be used as an induction agent for steroid-
dependent CD (remission rate 39.4% at 12 weeks) and for
maintenance of remission after successful induction (65% of
patients relapse-free after 40 weeks), and it is an alternative for
patients not responding to or intolerant to azathioprine or
6-mercaptopurine. However, methotrexate has the disadvantages
of potential myelosuppression, hepatotoxicity, and teratogenic
and abortigenic effects (Feagan et al. 1995, 2000).
Advances in the understanding of IBD pathogenesis have
permitted the development of agents (referred to as “biological
therapy”) directed against rational therapeutic targets, including
TNF-alfa antagonists such as infliximab and adalimumab (Caprilli
et al. 2005b). Infliximab was the first anti-TNF agent approved for
use in the management of CD, while adalimumab was approved
by the Food and Drug Administration (FDA) in the US and by the
Committee for Medicinal Products for Human Use (CHMP) in
Europe in 2007. Infliximab is an intravenously administered
chimeric mAb of the immunoglobulin G-1 (IgG1) subclass and is
comprised of 75% human and 25% mouse sequences.
Adalimumab is a subcutaneously administered, recombinant, fully
human IgG1 mAb specific for TNF-alfa. Both drugs can be used
for induction and maintenance of remission in patients with
moderate to severe active, steroid-refractory luminal CD, or with
fistulizing CD who are refractory to conventional medical therapy
(Ardizzone et al. 2002b; Rutgeerts et al. 2004; Plosker & Lyseng-
Williamson 2007).
In most clinical trials exploring biological therapies in CD, efficacy
has been evaluated using the Crohn’s Disease Activity Index
(CDAI), a score that combines both clinical and laboratory
parameters, where clinical remission is defined as a CDAI ≤150,
and clinical response can be defined either as a reduction in the
score of at least 70 (“70-point response”) or 100 points
(“100-point response”) compared with the basal value of >150,
with the latter being a more rigorous clinical result (Best et
al. 1976).
In the study by Targan et al. (1997) 81% of patients responded
(70-point response) to infliximab 5 mg/kg versus 17% for placebo
at 4 weeks. A total of 33% of patients treated with all infliximab
doses (5, 10, or 20 mg/kg) achieved remission versus 4% for
placebo. In the large (n=573) ACCENT I trial, 58% of patients
responded to a single open-label infusion of infliximab 5 mg/kg by
week 2 (Hanauer et al. 2002). At week 30, remission was
maintained in 39% and 45% of patients treated with infliximab
5 mg/kg and 10 mg/kg, respectively, compared with 21% of
placebo recipients. However, about 30% of patients with
refractory CD have consistently been found to be infliximab-
resistant. In addition, not all other patients are full responders.
Moreover, there is a loss of response to repeated infliximab
infusions in a proportion of patients, which seems unrelated to the
immunogenicity associated with the chimeric antibody. Finally,
the cost of biological therapies is high.
Regarding adalimumab, its clinical efficacy and safety in patients
with moderate to severe CD has been demonstrated in four
randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and
CLASSIC-II). The 4-week CLASSIC-I trial tested three induction
regimens of adalimumab versus placebo in 299 anti-TNF-naïve
patients: 1) adalimumab 40 mg at week 0 and 20 mg at week 2
(40 mg/20 mg); 2) adalimumab 80 mg at week 0 and 40 mg at
week 2 (80 mg/40 mg); 3) adalimumab 160 mg at week 0 and
80 mg at week 2 (160 mg/80 mg); or 4) placebo at weeks 0 and 2.
Adalimumab 80 mg/40 mg or 160 mg/80 mg was significantly
more effective than placebo for induction of remission in these
patients (24% vs 36% vs 12% at week 4; P=0.004) (Hanauer et al.
2006). Adalimumab 160 mg/80 mg was also more effective than
placebo for induction of remission in the 4-week GAIN study in
325 patients who developed loss of responsiveness or intolerance
to infliximab, where a remission rate of 21% was obtained at
week 4 compared with 7% of placebo recipients (P<0.001)
(Rutgeerts et al. 2006). In the 56-week CHARM study,
854 patients were treated with adalimumab 80 mg/40 mg in a
4-week open-label induction phase, where 58% achieved
remission at week 4. These responders (n=499) were then
randomized to 1 year of maintenance therapy with adalimumab
40 mg weekly or every other week, or placebo through week 56.
Higher remission rates were achieved with adalimumab every
other week or weekly compared with placebo (36% vs 41% vs
12%, respectively, at week 56; P<0.001). Moreover, the two
regimens of adalimumab were more effective than placebo in
complete fistula closure (Colombel et al. 2007a). Finally, in
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CLASSIC-II, an extension of the CLASSIC-I trial, 55 patients in
remission after a short course of adalimumab (40 mg at week 0
and 2) rerandomized to adalimumab 40 mg every other week or
weekly showed higher remission rates after 56 weeks than
patients receiving placebo (79% vs 83% vs 44%; P<0.05)
(Sandborn et al. 2007a).
Unmet needs
The limitation in both efficacy and safety encountered with the
current medical approaches for CD continues to drive the
search for better therapeutic agents.
The therapeutic use of murine mAbs in humans is considerably
limited by issues relating to immunogenicity. Chimeric
antibodies such as infliximab can induce strong human
antichimeric antibody (HACA) responses when administered
to patients; these are referred to as antibodies to infliximab
(ATI) and have been detected in 30–61% of patients treated
with episodic infliximab treatment compared with 7–10%
of patients on a scheduled infliximab regimen (Baert et al.
2003; Farrell et al. 2003; Hanauer et al. 2004). In the treatment
of chronic disorders (e.g. CD), where large or repeat doses
of mAbs may be required, the potential consequences of
HACA are a shortening of the mAb half-life in serum and
a secondary loss of efficacy, in addition to potential infusion
reactions, kidney damage, and serum sickness. In addition,
humanized antibodies such as adalimumab can induce the
development of antibodies called human antihuman antibodies
(HAHA), thus underlining that despite the reduction in the
mouse content of these mAbs, this is not a guarantee of a
completely nonimmunogenic molecule.
The induction of ATI with infliximab can be reduced by
concomitant administration of corticosteroids and
immunosuppressant agents such as methotrexate or
azathioprine. ATI incidence was 46% in patients receiving
concomitant immunosuppressors compared with 73% if no
concomitant immunosuppressors were given (P<0.001) in a
recent study (Vermeire et al. 2007). However, this is at the
expense of related side effects, including a potential long-term
risk of malignancies such as lymphoma, and an increased risk
of infections.
It has been shown that treatment with infliximab may also be
associated with occurrence of antibodies to double-stranded
DNA (23–34%) and antinuclear antibodies (45–56%); symptoms
of drug-induced lupus, however, occurred in only 0.2% of
patients (Hanauer et al. 2002; Sands et al. 2004).
Besides immunogenicity, several other factors limit the use of
infliximab, such as toxicity, cardiovascular and autoimmune
disorders, demyelinating disease, and a 1% mortality rate,
reported in 500 patients after a median follow-up of
17 (range, 0–48) months (Colombel et al. 2004). Moreover, an
infusion reaction rate of 16–21% has been reported (with
headache, dizziness, nausea, injection-site irritation, flushing,
chest pain, dyspnea, or pruritus) compared with 9–17% with
placebo, and infections in 30–34% of patients (most frequently
respiratory and urinary tract infections, including opportunistic
infections and active tuberculosis), compared with 27–37%
with placebo (Ljung et al. 2004; Blonski & Lichtenstein 2006a).
In the effort to improve anti-TNF treatment, new agents
targeting this cytokine have been designed and tested in
clinical trials. It is generally believed, but not yet proven, that
the amount of murine protein present in monoclonal antibodies
is directly related to immunogenicity. Significant progresses
have been made in the development of humanized forms
of anti-TNF compounds in order to improve this aspect
(Table 2); these include adalimumab, CZP, CDP571, etanercept,
and onercept.
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Characteristic Certolizumab pegol Etanercept Adalimumab Infliximab
Structure Pegylated humanized Fab’
fragment of an anti-TNF-alfa
mAb. No Fc region
Fusion protein: human TNF-R
p75 monomer fused with Fc
domain of human IgG1
Recombinant human
IgF1 mAb
Chimeric mouse-human
IgG1 mAb
Conjugate PEG No No No
Route of delivery s.c. injection s.c. injection s.c. injection i.v. infusion
Half-life (days) 14 4.8 14–19 8–10
Dosing frequency Monthly Twice weekly Injection every 2 weeks Infusion every 8 weeks
Manufacture Microbial fermentation Expression in mammalian
cell lines
Expression in mammalian
cell lines
Expression in mammalian
cell lines
TNF-alfa binding Soluble and membrane-bound Soluble and membrane-bound Soluble and membrane-bound Soluble, membrane-, and
receptor-bound
Affinity for TNF-alfa (KD, pM) 89.3 NA 157.4 227.2
Potency (IC90, ng/mL) 0.4 NA 6 5
Apoptosis No Yes? Yes Yes
ADCC/CDC No Yes Yes Yes
ADCC, antibody-dependent T-cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity; IC90, concentration of drug needed to inhibit viral replication by 90%; Ig, immunoglobulin;
i.v., intravenous; mAb, monoclonal antibody; NA, not applicable; PEG, polyethylene glycol; s.c., subcutaneous; TNF(-R), tumor necrosis factor (receptor).
Table 2 | Pharmacologic characteristics of anti-TNF agents (adapted from Weir et al. 2006)
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Besides searching for new effective compounds, recent studies
have focused on possible development of different cultural
approaches to the disease; this is the case for the previously
referred to “top-down” strategy, in the effort to improve the
clinical results achieved with the classical step-up approach and
with the potential ability to alter the natural history of CD. To date,
anti-TNF therapy has been reserved for patients with refractory
disease who have not responded to corticosteroids and
immunosuppressants (Lowenberg et al. 2006). Recently, the more
aggressive top-down therapeutic strategy was used early in the
disease course to find out whether this would lead to better
clinical outcomes, as suggested by a preliminary study, available
only in abstract form (Hommes et al. 2006). While top-down
therapy appears to have many advantages, its potential for
immunogenicity, loss of response, cost, and long-term safety
issues may somewhat limit its wholesale application. Instead, a
“risk-stratified” top-down approach may emerge, where those at
risk for worse outcomes are initially treated with more aggressive
therapy. At this point, however, the tools to identify such high-risk
patients remain crude (Orlando et al. 2005).
Controlled trials offer the best means to establish clinical efficacy
and to identify the most common side effects of a therapy. The risk
of a hurried and uncritical reception of positive results—however
modest—should be considered for any CD drug, but even more so
for compounds where economic and safety implications are
important. This situation has already occurred with previous
compounds, including a successful drug such as infliximab,
although we can now benefit from a longer period of clinical
knowledge and use. On the other hand, it is not time to make such
a judgment with CZP too, or other new anti-TNF-alfa agents. In
this paper we would like to stress some truths that the turbulent
“ideal world” of clinical trials may forget. Firstly, it should be
remembered that “statistical significance” does not always reflect
“clinical significance.” Second, in designing a clinical efficacy
protocol, the need to establish adequate therapeutic targets
instead of creating any surrogates that emphasise otherwise
modest results should be underlined. Although the use of
response rate may be more efficient in determining drug efficacy,
it does appear to be particularly susceptible to a high placebo
effect; in this regard, remission rates may be a more appropriate
and clinically meaningful primary endpoint (Winter et al. 2006).
Third, it is worthwhile pointing out that CDAI, on which most
randomized clinical trial results of CD have been based, is not a
perfect instrument, being influenced by many confounding factors,
and therefore does not always reflect the real correlation between
symptoms and disease activity. Other rigorous activity indexes
such as mucosal healing, or other important patient-oriented
parameters such as quality of life, should be evaluated in future
studies, although there is much debate about their accuracy.
In conclusion, it is our opinion that the main targets for any
therapy to be considered indicative of some efficacy in trials in CD
should be the induction and the maintenance of complete
remission that is at least clinically and, possibly, endoscopically
proven (instead of variably defined partial responses), and the
prevention of adverse events in order to improve patient
compliance, complication rate, and the need for surgery.
Clinical evidence with certolizumab pegol in
Crohn’s disease
Structure and pharmacokinetics
Since the inception of targeted antibody technologies in the
mid-1960s, immunotherapy has undergone a number of
developments to improve disease treatment and reduce
immunogenicity (Weir et al. 2006).
One of the most recent advances in antibody-based therapies is
the use of antibody fragments, including Fab’ fragments, as used
in CZP. CZP is a PEG-conjugated, humanized, Fc-free Fab’
fragment of an anti-TNF-alfa mAb (Blick & Curran 2007).
As with infliximab, adalimumab, and CDP571, the initial stage of
development of CZP consisted on the selection of an hybridoma
(designated HTNF40) secreting a high-affinity, potent murine IgG1
anti-TNF-alfa antibody. CZP was then obtained by grafting the
short hypervariable complementarity-determining regions (CDRs)
derived from HTNF40 onto an otherwise virtually human IgG Fab’
fragment (Weir et al. 2002). The CZP-Fab’ fragment can be
considered to have 98% human germline residues.
CZP differs from other anti-TNF agents in being univalent, while
adalimumab, etanercept, and infliximab are bivalent. A recent
study available only in abstract form suggests the pathologic
importance of this property. This stoichiometric study of binding
and complex formation with TNF by anti-TNF agents shows that
the bivalent antibodies adalimumab and infliximab crosslink TNF
trimers by binding to monomers in different trimers, while the
univalent structure of CZP does not permit it. The large immune
complexes formed by infliximab or adalimumab with TNF trimers
can cause degranulation and superoxide production by
neutrophils, thus inducing inflammation, while CZP does not
appear to cause these effects (Henry et al. 2007).
CZP exhibited a linear pharmacokinetic profile after
administration of a single subcutaneous 20, 60, or 200 mg dose
in six healthy volunteers in a randomized, double-blind, dose-
escalating study (Baker et al. 2006). Bioavailability of
subcutaneous CZP is high (estimated to be 100%) (Fossati &
Nesbitt 2005a,b). In healthy volunteers, the apparent volume of
distribution was 45 mL/kg, and clearance was 0.17 mL/h per kg
(modeled data) (Baker et al. 2006).
The small size of Fab’ fragments is generally accompanied by a
reduction in half-life in comparison to that of their parent Ig; the
IgG mAb has a half-life of 104 hours in rats, while the Fab’
fragment has a half-life of only 22.7 hours (Fossati & Nesbitt
2005a,b). In CZP, this short half-life is overcome by conjugation
with two molecules of PEG, prolonging in-vivo half-lives in rats to
45.8 hours, while in humans the elimination half-life is 192 hours
(i.e. about 2 weeks), comparable with that of full-length
humanized antibodies (Zalipsky 1995). The prolonged in-vivo half-
life is thought to be a result of reduced proteolysis (by avoidance
of cellular clearance) or excretion (by avoidance of renal clearance
as a result of the polymer increasing the apparent size of the
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molecule to above the glomerular filtration limit) (Rose-John &
Schooltink 2003). In addition to increasing the half-life, pegylation
offers other important potential advantages, including improved
thermal and mechanical stability, improved solubility in aqueous
solution, and improved bioavailability. The latter is 80–100% in
models after subcutaneous dosing. Overall, these
pharmacokinetic properties provide suitability for both
intravenous and subcutaneous administration (Baker et al. 2006).
Subcutaneous administration has potential advantages over the
intravenous route, in terms of convenience and safety owing to a
lack of infusion reactions.
Fab’ fragments have further benefits compared with full
antibodies in terms of ease of production. Because of the
necessity for glycosylation of the Fc portion of whole antibodies,
the currently marketed anti-TNF agents infliximab and
adalimumab are produced by expression in mammalian cell lines.
However, bulk production via mammalian cell lines is slow and
there is the potential for low product titers and production of
heterogeneous antibodies (Weir et al. 2002). Fab’ fragments such
as CZP do not require glycosylation. Moreover, CZP is
synthesized by fed-batch fermentation in Escherichia coli. These
aspects ensure a relatively simple, rapid (fermentation time of
3 days compared with 2–3 weeks), and reproducible process,
yielding a consistent and reliable supply of Fab’ fragments.
Biologic properties and pharmacodynamics
A difference among the available anti-TNF agents is related to the
ability of the IgG1 monoclonal antibodies infliximab, adalimumab,
and etanercept to fix complement. This is not the case for CZP
(Fossati & Nesbitt 2005c). Since it lacks the Fc portion of the
antibody, CZP only exerts its activity through binding to soluble
and membrane-bound TNF-alfa, and cannot bind to cell-surface
receptors for antibodies; consequently, complement fixation and
cell lysis do not occur. This results in a lack of the potentially
detrimental effects of complement-dependent cytotoxicity (CDC)
and antibody-dependent T-cell-mediated cytotoxicity (ADCC)
(Chapman 2002).
Another difference relates to the pharmacodynamic features of
CZP compared with other anti-TNF agents. Although all available
anti-TNF agents are capable of neutralizing soluble as well as
transmembrane forms of TNF-alfa, CZP has been shown to have
higher affinity and potency to TNF-alfa than infliximab and
adalimumab in vitro (Nesbitt & Henry 2004). A recent study
showed how CZP is more potent than all other anti-TNF agents in
inhibiting monocyte release of TNF-alfa and IL-1-beta induced by
lipopolysaccharide; in general, the ability to inhibit other cytokines
(IL-10, IL-12, granulocyte colony-stimulating factor, IL-1RA, MIP-
1-beta, TNF-RI, TNF-RII) has been observed for CZP as well as
for infliximab, adalimumab, and etanercept (Fossati et al. 2007).
Until now, neutralization of TNF-alfa alone has been considered
insufficient for clinical efficacy in patients with CD, while the
capacity to destroy TNF-alfa-expressing cells was thought to be
required. Infliximab, adalimumab, etanercept, and onercept, but
not CZP, are capable of inducing apoptosis of TNF-alfa-
expressing T cells and monocytes (Fossati & Nesbitt 2005c).
Apoptosis is a distinct mode of cell death and represents a crucial
regulatory mechanism to remove redundant cells in many
physiologic events. CD is indeed characterized by mucosal T-cell
proliferation that exceeds T-cell apoptosis (Ina et al. 1999).
Infliximab has been shown to restore the inappropriate T-cell
accumulation by induction of apoptosis (Ten Hove et al. 2002). An
interesting debate has emerged regarding the importance of T-cell
apoptosis to the clinical efficacy of CZP. Both CZP and infliximab
are effective in CD, yet while infliximab has been shown to induce
apoptosis, CZP lacks this property. Although in-vitro studies
showed the ability of infliximab to induce apoptosis in activated
T cells, the in-vivo clinical relevance of these findings remain
unclear. A recent in-vivo study using single photon emission
computed tomography (SPECT) with real visualization of
apoptosis has demonstrated that apoptosis in the intestine is
induced by chimeric anti-TNF treatment in both experimental
colitis and in human CD, where it can be predictive of efficacy of
anti-TNF treatment (Van den Brande et al. 2007). Despite these
data, onercept, although not effective in CD, is capable of
inducing apoptosis. It remains unclear, therefore, which of the
properties of TNF-alfa antagonists confers clinical efficacy in CD
(Chang & Lichtenstein 2006) and the specific role of apoptosis is
yet to be elucidated.
Phase II trials
Level 2 evidence from fully published studies investigating the
efficacy and safety of CZP is available, including placebo-
controlled studies (Winter et al. 2004; Schreiber et al. 2005a).
Administration of CZP by the intravenous route was first
investigated in a phase II trial by Winter et al. (2004). In this
randomized, single-dose, double-blind, placebo-controlled,
parallel-group, multicenter study involving 92 adult patients with
moderate to severe CD (CDAI 220–450), CZP 5, 10, or 20 mg/kg,
or placebo was administered over a 12-week period (two patients
received 1.25 mg/kg). These doses are higher than in normal
practice for subcutaneous delivery. The primary endpoint was the
percentage of patients achieving the 100-point response or
remission (CDAI ≤150) at week 4 in the intention-to-treat (ITT)
population. The percentage of patients achieving the primary
endpoint was comparable across all treatment groups (56.0%,
60.0%, 58.8%, and 47.8% for placebo, CZP 5, 10, and 20 mg/kg,
respectively). While no statistically significant difference in clinical
response was observed between CZP and placebo, clinical
benefit in terms of remission was demonstrated. A single
intravenous infusion of CZP 10 mg/kg induced remission at
2 weeks in a significantly greater number of patients (47.1%) than
placebo (16%, P=0.041) and was generally well tolerated. The
remission was ongoing at week 4 in CZP recipients, but at week
8 and 12 it was similar to the placebo group. It is worthy of
mention that a high placebo response rate was observed, and this
may partially explain the poor induction ability.
A successive phase II trial (Schreiber at al. 2005a) explored the
subcutaneous use of CZP in a multicenter, randomized, double-
blind, placebo-controlled, dose-ranging study. It was initially
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designed for a sample size of 260 to reach a power of 83% to
detect a difference of 23% between the treatment and placebo
groups. The study assumed a placebo response rate of 12% for
achieving their primary endpoints.
A total of 292 patients with moderate to severe CD (CDAI
220–450) was included and randomized to receive either placebo
or subcutaneous certolizumab 100 mg (n=74), 200 mg (n=72), and
400 mg (n=73) administered at 0, 4, and 8 weeks. The primary
endpoint was the percentage of patients achieving a clinical
response at week 12, defined as a decrease in CDAI score of at
least 100 points or remission (CDAI ≤150). The percentage of
patients showing a clinical response at weeks 2, 4, 6, 8, and 10,
was a secondary efficacy variable, as was the percentage of
patients in clinical remission (CDAI ≤150) at weeks 2, 4, 6, 8, 10,
and 12.
Two hundred and seven patients completed the study. In the
placebo group 24.7% of patients withdrew from the study by
week 12, compared with 29.7%, 20.8%, and 27.4% for the CZP
100 mg, 200 mg, and 400 mg treatment groups, respectively;
most of the withdrawals were a consequence of disease
progression (see Safety and tolerability for the adverse event rates
in this trial).
At all doses, CZP was able to reduce C-reactive protein (CRP)
concentrations at week 2 more efficiently than placebo. These
data support the antiinflammatory effect of CZP. The CZP doses
of 200 mg and 400 mg were more able to induce this biologic
response over the 12-week study period.
The onset of treatment clinical effect was rapid (Fig. 1a,b). Indeed,
at week 2 all doses of CZP induced a clinical response producing
a statistically significant benefit compared with placebo (29.7%
for CZP 100 mg, 30.6% for CZP 200 mg, and 33.3% for CZP
400 mg vs 15.1% for placebo). CZP 400 mg and 200 mg were
also superior to placebo in clinical response at week 4, while CZP
400 mg and 100 mg doses were better than placebo at week 8.
Only the 400 mg dosage maintained a better benefit than placebo
at week 10 (52.8% vs 30.1%; P=0.006), when the highest
response rate was observed. However, at the predefined primary
endpoint time (week 12), there were no significant differences
between the treatments (36.5% for CZP 100 mg, 36.1% for CZP
200 mg, and 44.4% for CZP 400 mg) and placebo group (35.6%).
Concerning the remission rates, all CZP doses induced
statistically higher percentage of remission than placebo at
week 4; CZP 400 mg and 100 mg were also better than placebo
at week 8 and, only for CZP 400 mg, also at week 10. However,
at week 12, this benefit was not confirmed, and the difference
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Fig. 1 | Clinical efficacy of subcutaneous CZP (adapted from Schreiber et al. 2005a with permission from Elsevier). *P<0.05; **P<0.01;
***P<0.001 vs placebo. CRP, C-reactive protein; CZP, Certolizumab pegol ITT. intent-to-treat
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between the CZP- and placebo-treated groups did not reach
statistical significance (27% for CZP 100 mg, 19.4% for CZP
200 mg, and 26.4% for CZP 400 mg vs 23.3% for placebo). The
authors found no difference in clinical response to CZP between
the patients who were taking concomitant immunosuppressants
and those who were not.
Both phase II trials failed to satisfy their primary endpoints,
suggesting a certain inability to induce remission. A review of the
data and debate ensued, when potential bias and confounding
elements that may have influenced the results emerged.
Firstly, an overall response rate of 36.6% and a remission rate of
23.3% were observed at week 12 in the placebo group. This
unexpected high placebo response rate may have contributed to
the apparent failure of the study agent. High placebo response
rate is common in randomized clinical trials in IBD. A meta
analysis of placebo-controlled, randomized clinical trials reported
that placebo rates for clinical remission ranged from 0% to 50%
and response rates ranged from 0% to 46% (Su et al. 2004). The
duration of studies was the most important predictor of placebo
remission and response. Given the 12-week length of the
Schreiber et al. (2005a) study, one would expect a foreseeable
rate of spontaneous response or remission. One would also
expect that extension of the study may have resulted in an
additional increase in the placebo response rate (Oikonomou &
Shen 2006).
Second, it is worthy of mention that although all patients had
symptoms indicating moderate to severe CD according to the
CDAI, only 41% had baseline serum CRP levels ≥10 mg/L.
Patients with low baseline CRP levels showed a particularly high
placebo response rate at week 12 (46.7%), compared with
38.1%, 38.6%, and 37.5% in the 100 mg, 200 mg, and 400 mg
CZP groups. The placebo response decreased with increasing
baseline CRP levels. These data may further explain the
unsatisfactory overall clinical effect, because patients with low
CRP levels may have problems not necessarily amenable to
antiinflammatory treatment.
In addition to these explanatory observations, a post-hoc analysis
not delineated in the original study was included and confirmed
the relationship between efficacy and CRP level. This analysis was
performed by stratification of patients according to CRP levels ≥ or
<10 mg/L. It was observed that in patients with a higher baseline
CRP level (n=119; 41% of patients as mentioned above), treatment
with CZP 400 mg resulted in a statistically significant benefit at all
time points throughout the 12-week study in terms of both clinical
response and remission rate (Fig. 1c,d). Specifically, a clinical
response or remission was achieved in 53.1% of patients with a
baseline CRP ≥10 mg/L when treated with CZP 400 mg, compared
with 17.9% of patients who received placebo (P=0.005).
Phase III trials
Level 2 evidence from fully published studies investigating the
efficacy and safety of CZP is available, including placebo-
controlled studies (Sandborn et al. 2007b; Schreiber et al. 2007b).
The PRECiSE (Pegylated Antibody Fragment Evaluation in
Crohn’s Disease: Safety and Efficacy) program, composed of four
studies (PRECiSE 1, 2, 3, and 4), represents a large,
comprehensive development program for CZP in CD, including
1328 patients, with a planned follow-up phase of up to 5 years.
In PRECiSE 2, a total of 668 patients with moderate to severe
active CD received open-label induction therapy with
subcutaneous CZP 400 mg given at 0, 2, and 4 weeks (Schreiber
et al. 2005b, 2007b). At week 6, patients who responded to
induction therapy (with at least a 100-point response) were
randomized in a double-blind phase to a maintenance regimen
with either CZP 400 mg every 4 weeks or placebo through week
24, with follow-up through week 26. Upon enrollment, patients
were stratified for CRP level (< or ≥10 mg/L), baseline steroid and
immunosuppressant use (Fig. 2). The primary endpoint was a
clinical response at week 26 in patients with a baseline CRP level
≥10 mg/L; secondary endpoints included response at week 26
and remission at week 26 in the ITT population, and remission in
the group with a baseline CRP level of at least 10 mg/L.
At week 6, CZP induced remission in 43% (n=289) and clinical
response in 64% (n=428) of patients among the overall
population; clinical response was 63.4% among those in the
higher CRP group. Compared to the data from the phase II trials
described above, these results showed similar positive effects
irrespective of baseline CRP levels.
At week 26, the 100-point clinical response rate and remission
rate (CDAI ≤150) were significantly higher following treatment with
CZP compared with placebo, again irrespective of CRP levels. In
particular, in the ITT population 63% maintained response at
week 26, compared with 36% in the placebo group (P<0.001) and
the remission rate was 48% in CZP recipients versus 29% of
Certolizumab | place in therapy review
Weeks 0 2 4 6 8 12 16 20 24 26
Doses
CZP open-label
induction phase
Identify
responders
Randomize 1:1
Randomized,
double-blind,
maintenance phase
Primary
endpoint
Nonresponders
Stratified for:
- CRP < or ≥10 mg/L
- baseline steroids and
 immunosuppressants
CDAI score
220-450 points inclusive
≥100-point drop in
CDAI responders
n=668
CZP 400 mg s.c. q 4 w
PRECiSE 3
PRECiSE 4
PRECiSE 3
PRECiSE 4
Discontinue
n=212
64%
n=216
Placebo q 4 w
Fig. 2 | PRECiSE 2 study design (adapted from Schreiber et al.
2007b). CDAI, Crohn’s Disease Activity Index;
CRP, C-reactive protein; CZP, certolizumab pegol;
s.c., subcutaneous; q 4 w, every 4 weeks
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patients who received maintenance with placebo (P<0.001)
(Fig. 3). Among those with high baseline CRP levels, response at
week 26 was 62% compared with 34% in the placebo group
(P<0.001), while the corresponding remission rate was 42%
compared with 26% (P=0.01). Prior and concomitant use of
immunosuppressants did not result in higher efficacy.
Patients were included only according to their CDAI at baseline,
indicating moderate to severe disease irrespective of prior
response to other drugs, including infliximab (primary failures to
infliximab were excluded, secondary failures were not). No data
are currently available from CZP studies in the specific subset of
patients previously treated with infliximab or not. This is required
to define the clinical role of CZP. Evidence-based data are
necessary to establish, for example, if CZP should be considered
a first-line drug (top-down strategy) or as treatment in resistant
patients. Regarding some of these aspects, subanalyses from
PRECiSE 2 have shown that CZP was effective in most patients
regardless of prior use of infliximab or concomitant
immunosuppressant or glucocorticoid treatment (Colombel et al.
2007c). Among the 668 baseline patients, 24.3% had received
prior infliximab, 34.9% were receiving immunosuppressants, and
40.5% were receiving glucocorticoids. Patients previously treated
with infliximab had slightly longer disease duration than
infliximab-naïve patients and a higher incidence of penetrating
disease; this pattern did not appear for concomitant
medications. Following the induction phase (CZP at weeks 0, 2,
and 4), responders were defined at week 6, and the clinical
response rates evaluated. At this time point, response rates
were similar in all subgroups, and this was maintained
through week 26. Compared with an overall response of 64.1%
at week 6, the corresponding rates according to concomitant
or prior drugs were as follows: 68.4% in infliximab-naïve
patients, 53.9% in patients receiving prior infliximab, 66.3%
in patients on immunosuppressants, 62.7% in patients not on
immunosuppressants, 62.9% in patients on glucocorticoids, and
64.8% in patients not on glucocorticoids. At week 26, response
rates were significantly greater with CZP than placebo in all
cohorts, irrespective of prior infliximab use: overall 62.8%
versus 36.2% (P<0.01), infliximab-naïve 68.7% vs 39.6%
(P<0.001), prior infliximab use 44.2% vs 25.5% (P=0.018), on
immuno-suppressants 61% vs 33% (P<0.001), not on immuno-
suppressants 64.% vs 39% (P<0.001), on glucocorticoids 57% vs
32% (P<0.002), 66% vs 39% (P<0.001) not on glucocorticoids. A
similar pattern was observed for remission at week 26, achieved
in 52.8% vs 33.3% of infliximab-naïve patients (P<0.001) and in
32.7% versus 13.7% of prior infliximab-treated patients
(P=0.008). In the overall population, remission at week 26 was
achieved in 47.9% vs 28.6% of patients in the CZP and placebo
groups, respectively.
These data suggest that CZP is effective irrespective of
concomitant treatment with immunosuppressants or
glucocorticoids; the slightly better results in the infliximab-naïve
group than in prior infliximab users can be influenced by the
different baseline characteristics of the included patients, such as
a longer disease duration in prior infliximab users indicating a
more resistant patient group. However, good results, although not
dramatic, are documented in both groups. A specific trial, named
WELCOME (26-Week Open-Label Trial Evaluating the Clinical
Benefit and Tolerability of Certolizumab Pegol Induction and
Maintenance in Patients Suffering from Crohn's Disease with Prior
Loss of Response or Intolerance to Infliximab), is currently
ongoing to further explore the efficacy of CZP in infliximab-
refractory or intolerant CD patients.
Interesting results from a further phase III trial (PRECiSE 1) have
also been presented (Sandborn et al. 2007b). The primary
outcomes were met, with benefits of CZP treatment over placebo,
regardless of baseline CRP levels. The PRECiSE 1 design is very
interesting and can give robust results. It is the first reported
phase III, double-blind, placebo-controlled study of an anti-TNF
agent extending to 26 weeks, without an unblinded induction
phase to preselect responders as the eligible patients to be
randomized at study baseline (Fig. 4).
In PRECiSE 1, a total of 660 patients with moderate to severe CD
(CDAI 220–450) were included and randomized to receive either
subcutaneous CZP 400 mg (n=331) or placebo, at weeks 0, 2, 4
and then every 4 weeks through to week 24. Patients were
primarily stratified according to baseline CRP levels (< or
≥10 mg/L) and immunosuppressant/corticosteroid use. The
primary endpoints were the percentage of patients in the CRP
≥10 mg/L stratum achieving a 100-point clinical response at week
6, and at week 6 and 26 combined. Secondary endpoints
included 70-point response, remission (CDAI ≤150), and median
CRP levels in the ITT population and in the high CRP stratum.
Among patients with a baseline CRP level ≥10 mg/L, a
significantly greater proportion of patients treated with CZP
achieved a 100-point response at week 6 (37% vs 26%; P<0.05)
and at week 6 and 26 combined (22% vs 12%; P<0.05),
compared with placebo. Similar significant efficacy for CZP over
Certolizumab | place in therapy review
100
80
60
40
20
0
Response Remission
All
(n=210/215)
CRP >10 mg/L
(n=101/112)
All
(n=210/215)
CRP >10 mg/L
(n=101/112)
P<0.001 P<0.001 P<0.001 P=0.01
36
63
34
62
29
48
26
42
3 injections + placebo
CZP 400 mg
%
o
f
p
at
ie
nt
s
Fig. 3 | PRECiSE 2: response and remission rate at week 26
(Schreiber et al. 2007b). CRP, C-reactive protein; CZP,
certolizumab pegol
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placebo was demonstrated for the 70-point response in a further
post-hoc analysis at the same time points. In addition, the
remission rate at week 4 was higher in the CZP group compared
with placebo (20% vs 10%; P<0.05), while a nonsignificant trend
in favor of CZP was observed at week 6 and at the combined
week 6 and 26 time point (Table 3). Among the ITT population, the
100-point response was significantly in favour of CZP at week 4
(29% vs 22%; P<0.05), at week 6 (35% vs 27%; P<0.05) and at
week 6 and 26 combined (23% vs 16%; P<0.05). On the other
hand, the remission rate was better in the CZP group only at week
4 (20% vs 11%; P<0.01), while at week 6 and week 6 and 26
combined the drug showed no significant difference (P=0.17) with
placebo (Table 3). Of interest, significantly more CZP recipients
achieved remission at week 26 (29.5% vs 18.3%; P<0.05).
Safety and tolerability
In both phase II trials the prevalence of adverse events, mostly
mild to moderate in intensity, was similar in both placebo and
active treatment groups (62.5–69.9% for placebo versus
63.2–73% for CZP; P value not reported). No deaths were
observed, nor were any cases of lymphoma, lupus, tuberculosis,
or opportunistic infections recorded, or anaphylaxis observed
(Blonski & Lichtenstein 2006b).
In the study by Winter et al. (2004) a total of 164 adverse events
were reported by 43 patients who received CZP. The most
common adverse events included headache (n=35), exacerbation
of CD (7), urinary tract infection (5), unspecified abdominal pain
(4), fever (4), and nausea (4). Of note, all urinary tract infections
occurred in the patients treated with active drug. Overall, nine
patients experienced a total of 11 serious adverse events during
the study period: 2% in the placebo group compared with 10.3%
in the CZP group, for all doses. The majority of serious events
were gastrointestinal. In the placebo group they included
exacerbation of CD (1) and erythematous rash (1). Serious
adverse events reported with CZP included aggravated CD (3),
abdominal pain (2), intestinal obstruction (2), perianal abscess (1),
and drug overdose (1). Eight of the 11 serious events were
considered to be unrelated to study drug, while the remaining
three events were considered possibly related (erythematous rash
in one patient given placebo; aggravated CD and perianal
abscess in CZP recipients).
In the study by Schreiber et al. (2005a) the most frequent adverse
events with CZP included headache (13.2% vs 16.4% for placebo),
aggravation of CD (11.9% vs 13.7%), nausea (11.4% vs 5.5%), and
nasopharyngitis (9.1% vs 4.1%). Others included dizziness
(excluding vertigo) (6.4% vs 4.1%), unspecified abdominal pain
(5.9% vs 5.5%), arthralgia (5.9% vs 2.7%), pharyngolaryngeal pain
(5% vs 5.5%), and fever (5% vs 4.1%). Infection was observed in
26.5% of CZP-treated patients versus 23.3% of the placebo group
during the double-blind period and in 14.2% versus 13.7% during
the safety follow-up period. The following serious adverse events
were reported, in decreasing order of frequency: worsening CD,
rectal hemorrhage, abdominal mass, reduced visual acuity, pyrexia,
vomiting and paralytic ileus, breast hyperplasia, ankle ulcer,
thrombocytopenia, and perianal abscess.
Whereas the study by Winter et al. (2004) did not report any
infusion reactions with the intravenous route, Schreiber and
colleagues (2005b) reported a higher incidence of injection-site
adverse events (burning, erythema, inflammation, pain, or rash)
among patients treated with active drug (5%) compared with
placebo (2.7%); the most common reaction occurring within
30 min of administration was injection site burning.
A combined analysis of tolerability data from PRECiSE 1 and
PRECiSE 2 has also been presented; this post-hoc review
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Fig. 4 | PRECiSE 1 study design (Sandborn et al. 2007b). CDAI,
Crohn’s Disease Activity Index; CRP, C-reactive protein;
CZP, certolizumab pegol; s.c., subcutaneous;
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Table 3 | PRECiSE 1: outcomes with CZP for the ITT
population and the CRP >10 mg/L stratum
(adapted from Crofskey 2006)
ITT population High CRP stratum
Placebo
(n=328)
CZP
(n=331)
Placebo
(n=156)
CZP
(n=146)
100-point response (%)
Week 4 21.8 28.7a 20.6 32.9a
Week 6 26.8 35.2a 26.0 37.2a
Week 6 and 26 16.0 23.1a 12.3 21.5a
70-point response (%)
Week 4 33.7 44.0b 30.3 50.3b
Week 6 37.8 46.2a 33.1 46.9a
Week 6 and 26 22.5 32.0b 14.9 29.2b
Remission
Week 4 11.3 19.5b 9.7 20.1
Week 6 17.2 21.6 16.9 21.9
Week 6 and 26 9.8 14.4 8.4 13.1
aP<0.05 vs placebo.
bP<0.01 vs placebo.
CRP, C-reactive protein; CZP, certolizumab pegol; ITT, intention to treat
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included a total of 1328 patients (Schreiber et al. 2007a). Data
from the double-blind phases of both trials showed that CZP was
generally well tolerated. The incidence of adverse events was
comparable in the CZP and placebo groups. Most adverse events
were of mild to moderate severity; overall, the most common
adverse events in patients receiving CZP were headache,
nasopharyngitis (in both studies), abdominal pain (PRECiSE 1),
and cough (PRECiSE 2). The most frequent infections were
nasopharyngitis, urinary tract infections, and upper respiratory
tract infections. The incidence of serious adverse events in
PRECiSE 1 was 10.3% in the CZP group and 7% in the placebo
group. Corresponding values during PRECiSE 2 were 6% and
7%. No cases of lupus were reported in either trial. The incidence
of malignancy was infrequent and similar between treatment
groups in the PRECiSE 1 trial (two patients in each group: one
metastatic lung cancer in a 22-year-old male previously treated
with multiple infliximab infusions and azathioprine, methotrexate,
and corticosteroids, and one rectal carcinoma in a 44-year-old
man, in the CZP group; one Hodgkin’s lymphoma in a 33-year-old
man, and one cervical carcinoma in situ in a 21-year-old woman
for placebo). No malignancies were reported in PRECiSE 2. In
PRECiSE 2, one case of tuberculosis, which responded well to
antituberculosis therapy, was observed. Injection reactions were
uncommon and less frequent with CZP than placebo (3% vs 15%
in PRECiSE 2; 3% vs 14% in PRECiSE 1). One death occurred in
the CZP group of each study (one acute myocardial infarction in
the already cited 22-year-old male with hypertensive heart
disease and metastatic lung cancer 10 months after withdrawal
from the study; one accidental fentanyl overdose in PRECiSE 2);
neither was considered treatment-related.
A combined interim analysis on long-term safety in PRECiSE 3
and 4, available only in abstract form, showed no new safety
signals of concern (Colombel et al. 2007d).
These data seem to indicate a good safety profile of CZP, with a
lower adverse-event rate than other anti-TNF agents. It is,
however, worth nothing that the reported incidences of adverse
events from PRECiSE 1 and 2 refer to the double-blind phase—
therefore the open-label section of PRECiSE 2 with
6 weeks of first exposure to CZP would have been excluded. It is
interesting to note that the higher rates of serious adverse events
for CZP were seen in PRECiSE 1, which also had a randomized
induction phase.
Immunogenicity
It is well known that the administration of any protein, including
those that are fully human, may be associated with the
development of antibodies (Fefferman & Farrell 2005). The
mechanisms underlying a protein’s immunogenicity are complex
and poorly understood and go far beyond the species from which
a therapeutic protein is derived. Humanization of therapeutic
antibodies diminishes but does not abolish the risk of antidrug
antibodies (Van Assche et al. 2006).
Anti-CZP antibodies levels were low or undetectable using
enzyme-linked immunosorbent assay (ELISA) after a single
intravenous infusion (1, 5, or 20 mg/kg) in patients with
rheumatoid arthritis, while antibodies were detected in all
treatment groups after a treatment cycle, with lower incidence in
patients treated with higher doses (Choy et al. 2002).
The study by Schreiber et al. (2005b) showed that 12.3% of
patients receiving CZP 400 mg had at least one positive result for
anti-CZP antibodies. However, no decrease in efficacy was seen,
since the proportion of responders patients at week 12 was
similar in antibody-positive and -negative patients, with 44% of
patients responding in both subgroups. The study has not
provided data on the correlation between concomitant
corticosteroids or immunomodulators use and the development
of antibodies (only 37.5% of the patients from CZP 400 mg group
were on concomitant immunomodulators at baseline). In
PRECiSE 1 and 2 the occurrence of anti-CZP antibodies was
reported in 8% and 9% of patients, respectively (Sandborn et al.
2007b; Schreiber et al. 2007b).
Moreover, anti-infliximab antibodies did not cross-react with CZP
in 20 patients with CD (Vetterlein et al. 2006), where anti-CZP
antibody levels were undetectable, thus suggesting that CZP can
be used in patients who develop an antibody response to
infliximab. On the other hand, antibodies to CZP did not cross-
react with adalimumab, etanercept, or infliximab in 22 patients
with CD, thus suggesting that patients initially treated with CZP
could subsequently receive other anti-TNF agents with no risk of
cross-reactivity (Vetterlein et al. 2007).
Autoantibody production for antinuclear antibodies was
reported at week 26 in 2% of CZP recipients versus 1% of
placebo recipients in PRECISE 1, and was reported in 8% vs
1% in PRECISE 2; corresponding values for antidouble-
stranded DNA antibodies were 1% for patients receiving CZP
versus 1% for patients receiving placebo in PRECiSE 1 and 1%
versus 0.6% in PRECiSE 2 (Sandborn et al. 2007b; Schreiber et
al. 2007b).
Preliminary data from PRECiSE 3 and 4, available only in abstract
form, show positivity to antinuclear antibodies in 14.1% and 3%,
respectively, and antidouble-stranded DNA in 3.2% and 2.7%,
respectively in PRECiSE 3 and 4 (Colombel et al. 2007d).
Quality of life
Marginal improvement in quality of life (P=0.05) was observed in
the CZP 400 mg group compared with placebo in the phase II trial
by Schreiber et al. (2005a). Clinically meaningful improvements in
Inflammatory Bowel Disease Questionnaire (IBD-Q) total score
(16-point increase) were seen in 52.8% of patients in the CZP
400 mg group at week 2 (vs 32.9% in placebo group), increasing
to 66.7% at week 12 (vs 50.7% in placebo group).
In PRECiSE 1, 42% of patients had an IBD-Q response at week
26, compared with 33% in placebo recipients (P=0.01), while the
corresponding values during PRECiSE 2 were 60% and 43%
(P<0.001) at week 26 (Sandborn et al. 2007b; Schreiber et
al. 2007b).
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Some subanalyses from PRECiSE 1 and 2, available in abstract
form, have further focused on quality of life in CZP-treated
patients. Firstly, CZP improved health-related quality of life in
CD, assessed through the IBD-Q at week 6, 16 and 26. Both
after the induction phase (week 6) and at the end of the
maintenance phase (week 26), quality of life improved in CZP
recipients at levels that are indicative of remission (from a mean
of 122.6 points at week 0 to a mean of 174.8 points at week 6
and a mean of 175.7 points at week 26) and in all the four
domains of the IBD-Q (Table 4). Moreover, at week 26 a
significantly higher IBD-Q response (increase in total score
from baseline >16 points) in the CZP group than placebo was
observed (Feagan et al. 2007b). CZP has been shown to
improve work productivity and the ability to perform daily
activities, as assessed through the work productivity and
activity impairment (WPAI) questionnaire, at week 0, 6, 16, and
26, regarding all four dimensions and impairment scores
(absenteeism, presenteeism, overall work impairment, and daily
activities impairment) (Feagan et al. 2007a,c).
Certolizumab pegol in top-down algorithms
At present, no trials have directly investigated the use of CZP
as first-line treatment of newly diagnosed CD patients. Only
indirect data are available from post-hoc subanalyses of
PRECiSE 2 (Schreiber et al. 2006; Colombel et al. 2007b). In the
subanalysis by Schreiber et al. (2006), the rates of response
and remission at week 26 in the overall ITT population were
explored according to disease duration at baseline. Overall,
CZP was superior to placebo for maintenance at week 26,
irrespective of disease duration. Induction rates were similar
across all groups regardless of disease duration. The
proportion of patients in response and remission on
maintenance therapy at week 26 was inversely correlated with
disease duration (Table 5). In recently diagnosed patients (time
from diagnosis <1 year), CZP maintained a response in 89.5%
of the subgroup and a remission in 68.4% vs 37.1% in the
placebo groups. These data seem to suggest a benefit from
early intervention with CZP for the long-term maintenance of
response and remission in patients with active CD.
Specific trials primarily designed to confirm these results are
needed, in addition to the need to demonstrate a real disease-
modifying benefit.
Ongoing studies
PRECiSE 3 and 4 are both long-term (up to 5 years) open-label
trials assessing the longer-term efficacy, safety, and tolerability of
CZP in patients from PRECiSE 1 and PRECiSE 2, and are
currently ongoing. Briefly, at week 26, completers of PRECiSE 1
and 2 who participate in PRECiSE 3 receive CZP 400 mg every
4 weeks for up to 5 years (Fig. 5). In PRECiSE 4, patients who
relapsed after week 2 in PRECiSE 1 (Fig. 4) or after randomization
in PRECiSE 2 (Fig. 2), receive reinduction with CZP 400 mg (three
doses at week 0, 2, and 4) followed by maintenance dosing every
4 weeks (Fig. 6). Relapse was defined as a CDAI increase of
>70 points or absolute CDAI >350. For patients who relapsed
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IBD-Q domain Mean IBD-Q score
Induction phase Maintenance phase
CZP Placebo CZP
Week 0 Week 6 Week 26 Week 26 P value
Total score 122.6 174.8 167.9 175.7 0.001
Bowel
symptoms
38.6 54.7 51.8 54.7 0.001
Systemic
symptoms
15.7 24.7 23.9 25.3 0.001
Emotional
function
47.1 65.4 62.6 65.6 0.002
Social
function
21.2 30.0 29.5 30.1 0.048
CZP, certolizumab pegol; IBD-Q, irritable bowel disease questionnaire.
Table 4 | Effect of treatment with CZP on the IBD-Q score
changes from baseline (Feagan et al. 2007b)
Time from
diagnosis
Response Remission
Placebo, % (n) CZP, % (n) Placebo, % (n) CZP, % (n)
Any 36.2 (210) 62.8a (215) 28.6 (210) 47.9a (215)
<1 year 37.1 (35) 89.5b (19) 37.1 (35) 68.4c (19)
1–2 years 50.0 (22) 75.0 (20) 36.4 (22) 55.0 (20)
2–5 years 36.4 (55) 62.2c (45) 29.1 (55) 46.7 (45)
≥5 years 32.7 (98) 57.3a (131) 23.5 (98) 44.3a (131)
aP<0.001 vs placebo.
bP<0.01 vs placebo.
cP<0.05 vs placebo.
CZP, certolizumab pegol.
Table 5 | PRECiSE 2 subanalysis: response and remission
rates according to treatment and disease duration at
week 26 (adapted from Schreiber et al. 2006)
Weeks 26 28 30 32 36 40 44 48 52 56
Doses
60 64 68 72 76 80
PRECiSE 3
CZP 400 mg
PRECiSE 2
CZP 400 mg
induction
and maintenance PRECiSE 2
CZP 400 mg
induction
then placebo
PRECiSE 1
CZP 400 mg
induction
and maintenance
Fig. 5 | PRECiSE 3 study design (Schreiber et al. 2007c). CZP,
certolizumab pegol
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despite maintenance therapy with CZP, reinduction constitutes a
single additional dose at week 2, compared with the PRECiSE 1
and 2 regimen. PRECiSE 3 and 4 use the Harvey–Bradshaw Index
for assessment of efficacy. Preliminary results from these two
trials have recently been presented as an interim analysis in
abstract form, showing the drug’s ability to maintain long-term
remission and to reinduce clinical response in “withdrawal”
patients (Sandborn et al 2007c; Schreiber et al. 2007c).
Enrollment is also currently ongoing in the phase IIIb, multicenter
clinical trial, WELCOME, designed to examine the effects of CZP
in patients failing or intolerant to infliximab. In addition, the
MUSIC study (Mucosal Study in Crohn’s disease) will investigate
the impact of CZP on endoscopic and mucosal healing, and the
multicenter, randomized, placebo-controlled, phase IIIb CONCISE
trial (Corticosteroid-sparing Effect of Certolizumab Pegol in
Patients with Moderately Severe Crohn's Disease who are
currently in remission with corticosteroid treatment) will examine
the corticosteroid-sparing effect of CZP in CD.
Economic evidence
At present, economic evidence comparing the use of CZP with
other drugs is not available. Using its proprietary low-cost E. coli
technology to produce Fab’ fragments, the developer has
declared that it will be able to lower the manufacturing costs of
CZP by 10- to 20-fold compared with antibodies conventionally
produced in mammalian cell culture, although, on the other
hand, pegylation may be costly. However, the price of CZP has
not yet been determined.
Until results from ongoing clinical trials are available and the
price is determined, an estimate of the potential impact on
patients and healthcare systems cannot be made. As CZP may
be indicated for moderately affected as well as severely affected
patients, the patient group may be larger than that for infliximab
and may have a greater impact on costs, although this is very
speculative. CZP is delivered as a subcutaneous injection; this
may lead to some savings in staff time and associated costs.
Patient group/population
It is necessary to await results from currently ongoing trials that, in
addition to those available from available studies, will definitively
investigate the efficacy and safety profile of CZP in all the possible
clinical scenarios in CD.
Data from PRECiSE 1–4 may suggest a role for CZP in the
classical scenario of corticosteroid use, i.e. induction of remission
in moderately to severely active CD, and its successive long-term
maintenance. Moreover, data from WELCOME could suggest a
role for CZP in refractory CD similar to that of infliximab, or a
possible place as salvage therapy in patients refractory or
intolerant to this drug.
No data are available for fistulizing disease or for extra-
intestinal manifestations.
Dosage, administration, and formulations
Official dosage recommendations are not yet available. In clinical
trials CZP was delivered by subcutaneous injection (lyophilized) as
a 200 mg vial for single use in a 5 mL vial reconstituted with water
for injection. The maximum volume that can be given by
subcutaneous injection at a single injection site is 1 mL.
The dosage of CZP that has demonstrated the better efficacy in
clinical trials is 400 mg administered subcutaneously, so two
subcutaneous injections of 200 mg are given in two different sites;
suitable areas for injection are the lateral abdominal wall or upper
outer thigh. The scheduled regimen was administration at week 0,
2, and 4 (induction phase) and then every 4 weeks from week 6
(maintenance phase), although the WELCOME study is exploring
the efficacy of a more frequent (every 2 weeks) maintenance
regimen. Concomitant use of immunosuppressants does not
appear to be necessary.
Place in therapy
The pharmacologic characteristics of CZP are interesting and may
theoretically provide a good safety and long-term efficacy profile,
as well as more practical (easier subcutaneous use) and
economical (easier production cycle) features. From this point of
view, CZP could be a useful addition to the anti-TNF treatments of
CD. Whether CZP could be useful as a rescue therapy for patients
who have failed infliximab is still to be determined, and a trial
specifically investigating this is currently ongoing. At present it is
also difficult to suggest a role as a substitute for other anti-TNF
agents in moderate to severe refractory CD because of the lack of
any definitive comparative studies with infliximab or adalimumab.
The PRECiSE 1 study indicates that in patients with moderate to
severe CD, induction and maintenance therapy with CZP is
associated with a modest improvement in response rates, but with
Certolizumab | place in therapy review
Weeks 0 2 4 8 12 16 20 24 28 32
Doses
36 40 44 48 52
PRECiSE 4
CZP 400 mg
PRECiSE 2
CZP 400 mg
induction
and maintenance PRECiSE 2
CZP 400 mg
induction
then placebo
PRECiSE 1
CZP 400 mg
induction
and maintenance
Fig. 6 | PRECiSE 4 study design (Schreiber et al. 2007c). CZP,
certolizumab pegol
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no significant improvement in remission rates; moreover, the
absolute difference in the rate of response between CZP and
placebo group was relatively small (Sandborn et al. 2007b). Based
on these data, the question arises whether physicians will want to
compromise on efficacy for the potential of better long-term safety
(Rutgeerts et al. 2004). However, the results of currently available
induction trials cannot be compared with trial results obtained with
the other anti-TNF agents infliximab or adalimumab, since they had
different design and duration, and therefore we do not know whether
the findings are reproducible (Lewis 2007). Data concerning the
induction efficacy of CZP differed among the double-blind PRECiSE
1 trial (35%), the double-blind phase II trial (45%), and the open-
label phase of the PRECiSE 2 trial (64%) (Schreiber et al. 2005a,
2007a; Sandborn et al. 2007a). It is therefore not a surprise that the
FDA has requested more data on the induction efficacy of CZP.
More interesting results concern the efficacy of CZP as a
maintenance therapy when the drug has induced a response. The
PRECiSE 2 trial shows that maintenance therapy with CZP is
effective in patients with moderate to severe CD who had responded
to open-label induction therapy with CZP (Schreiber et al. 2007b), as
occurred in similarly designed trials with infliximab and adalimumab.
Once again, however, a direct comparison of the maintenance
results between trials is not appropriate at this time, and selection
between the various anti-TNF agents should be made on the basis
of comparative studies. Unfortunately, it is unlikely that such
comparative trials will be conducted. Thus, the final choice of
therapy will have to take into account other factors, such as costs
and convenience for patients (Lewis 2007).
It is also difficult to establish a certain role for CZP as first-line
treatment in moderately to severely active CD, unless a significant
positive effect on the natural course of the disease can be
demonstrated. The safety and economic profile of CZP, compared
with available drugs (corticosteroids) also has to be considered in
this scenario.
CZP, as well as adalimumab, is administered subcutaneously, which
can be an important benefit in patients who have difficult venous
access, and may avoid intravenous catheters. Self-administration
may make it more difficult to monitor adherence to therapy, although
it may also make patients more active participants in their own care,
thus increasing compliance. Self-administration can also decrease
indirect costs, such as recruitment of medical practitioners or time
lost from work. What effect self-administration may have on safety
is unknown.
In conclusion, CZP is very promising and deserves attention but
more studies, some of them in press or already ongoing, and the
subsequent clinical application of the drug will provide the real
definitive evidence for its use in CD.
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